J&J Medical Connect
TALVEY®

(talquetamab-tgvs)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TALVEY® (talquetamab-tgvs)

Medical Information

TALVEY - Occurrence and Management of Hematologic Adverse Events

Last Updated: 02/11/2026

SUMMARY

  • Johnson & Johnson does not recommend the use of TALVEY in a manner that is inconsistent with the approved labeling.
  • This response provides relevant data from company-sponsored clinical trials, and the content is limited to the studies included below.
  • MonumenTAL-1 is an ongoing, open-label, phase 1/2 study evaluating the efficacy and safety of TALVEY in patients with relapsed or refractory multiple myeloma (RRMM) after ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI), an immunomodulatory drug, and an anti-CD38 monoclonal antibody (mAb).1
    • Rasche et al (2025)2 presented the incidence of hematologic AEs from the MonumenTAL-1 study at an extended median follow-up of 38.2 months for the 0.4 mg/kg subcutaneous (SC) weekly (QW) cohort, 31.2 months for the 0.8 mg/kg SC every other week (Q2W) cohort, and 30.3 months for the prior T-cell redirection therapy (TCR)-exposed (QW and Q2W) cohorts.
    • Chari et al (2025)1 published the incidence of hematologic AEs from a post hoc analysis of phases 1 and 2 of the MonumenTAL-1 study at a median follow-up of 25.6 months for the 0.4 mg/kg SC QW cohort, 19.4 months for the 0.8 mg/kg SC Q2W cohort, and 16.8 months for the prior TCR-exposed cohort.
    • Schinke et al (2023)3 presented the incidence of hematologic AEs from the phase 2 portion of MonumenTAL-1 study at a median follow-up of 18.8 months for the 0.4 mg/kg SC QW cohort, 12.7 months for the 0.8 mg/kg SC Q2W cohort, and 14.8 months for the prior TCR-exposed cohort.
  • MonumenTAL-2 is an ongoing, phase 1b, multi-arm, open-label study evaluating TALVEY in combination with other anticancer therapies in patients with multiple myeloma (MM).4-6
    • Cohort D is evaluating the efficacy and safety of TALVEY + DARZALEX FASPRO® (daratumumab hyaluronidase) and lenalidomide in 34 patients with newly diagnosed multiple myeloma (NDMM).6
      • Nooka et al (2024)6 presented the incidence of hematologic AEs of the TALVEY 0.6 mg/kg Q2W + DARZALEX FASPRO + lenalidomide cohort at a median follow-up of 13.2 months and the TALVEY 0.8 mg/kg every 4 weeks (Q4W) + DARZALEX FASPRO + lenalidomide cohort at a median follow-up of 5.8 months.
    • Cohort E is evaluating the safety and efficacy of TALVEY + pomalidomide in 35 patients with RRMM.4
      • Quach et al (2025)4 presented the incidence of hematologic AEs from the TALVEY + pomalidomide cohort of the MonumenTAL-2 study at a longer median follow-up of 20.7 months.
  • RedirecTT-1 is an ongoing, open-label, phase 1b/2 study evaluating the safety and efficacy of the TALVEY and TECVAYLI® (teclistamab-cqyv) combination in patients with RRMM, including those with extramedullary disease (EMD).7-10
    • Usmani et al (2025)7 presented the incidence of hematologic AEs from phase 2 of the RedirecTT-1 study in patients with RRMM and EMD at a median follow-up of 16.8 months.
    • Kumar et al (2025)8 published the incidence of hematologic AEs from phase 2 of the RedirecTT-1 study in patients with RRMM and EMD at a median follow-up of 12.6 months.
    • Mateos et al (2025)9 presented the incidence of hematologic AEs from phase 1b of the RedirecTT-1 study across all dose levels (dose levels 1-5) at a median follow up of 38 months, in patients with RRMM, including those with EMD.
    • Cohen et al (2025)10 published the incidence of hematologic AEs from the phase 1 dose-escalation segment of the RedirecTT-1 study at a median follow-up of 20.3 months across dose levels (dose levels 1-5).
  • TRIMM-2 is an ongoing, phase 1b, multicohort open-label study evaluating the efficacy and safety of DARZALEX FASPRO + TECVAYLI or TALVEY with or without pomalidomide in patients with RRMM.11-13
    • Chari et al (2025)12 published the incidence of hematologic AEs in the TALVEY 0.4 mg/kg QW + DARZALEX FASPRO and the TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO cohorts at a median follow-up of 18.6 months (range, 1.2-39.1).
    • Bahlis et al (2024)11 presented the incidence of hematologic AEs in the TALVEY 0.4 mg/kg QW + DARZALEX FASPRO + pomalidomide cohort at a median follow-up of 15.8 months and the TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO + pomalidomide cohort at a median follow-up of 17.5 months.
  • TRIMM-3 is a phase 1b, nonrandomized, open-label study evaluating the dosing, safety, and tolerability of a programmed cell death receptor-1 (PD-1) inhibitor in combination with TALVEY or TECVAYLI in patients with RRMM.14,15 
    • Perrot et al (2025)14 presented the incidence of hematologic AEs of the TALVEY + cetrelimab cohort at a median follow-up of 11.5 months.

PRODUCT LABELING

CLINICAL DATA - Monumental-1 Study

MonumenTAL-1 (NCT03399799, NCT04634552) is a phase 1/2 study of TALVEY in patients with RRMM.1

Study Design/Methods (Phase 2)

Patients were enrolled into 1 of the following 4 cohorts:

  • TCR naive: 0.4 mg/kg SC QW, not previously exposed to TCR such as chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAbs; prior B-cell maturation antigen [BCMA] antibody-drug conjugate [ADC] allowed).3,16
  • TCR naive: 0.8 mg/kg SC Q2W, not previously exposed to TCRs (prior BCMA ADC allowed).3,16
  • TCR exposed: 0.4 mg/kg SC QW or 0.8 mg/kg SC Q2W, have been previously exposed to TCRs.3,16
    • Among the prior TCR-exposed cohort, patients were divided based on type of TCR (CAR-T, BsAb, or CAR-T and BsAb).
  • Key eligibility criteria1:
    • ≥18 years of age, measurable MM per International Myeloma Working Group (IMWG) criteria.
    • ≥3 prior LOTs including a PI, an immunomodulatory drug, and an anti-CD38 mAb.
    • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2.

Rasche et al (2025)2 presented the incidence of hematologic AEs from the MonumenTAL-1 study at an extended median follow-up of 38.2 months for the 0.4 mg/kg SC QW cohort, 31.2 months for the 0.8 mg/kg SC Q2W cohort, and 30.3 months for the prior TCR-exposed (QW and Q2W) cohorts.

Safety Results


MonumenTAL-1 Study: Hematologic AEs (≥30% in Any Cohort)2
AE, n (%)
0.4 mg/kg SC QW (n=143)
0.8 mg/kg SC Q2W (n=154)
Prior TCR
QW and Q2W
(n=78)
Any Grade
Grade 3/4
Any Grade
Grade 3/4
Any Grade
Grade 3/4
Anemia
65 (45.5)
46 (32.2)
67 (43.5)
39 (25.3)
38 (48.7)
22 (28.2)
Neutropenia
50 (35.0)
44 (30.8)
44 (28.6)
33 (21.4)
40 (51.3)
37 (47.4)
Thrombocytopenia
39 (27.3)
29 (20.3)
46 (29.9)
28 (18.2)
30 (38.5)
22 (28.2)
Abbreviations: AE, adverse event; Q2W, every other week; QW, weekly, SC, subcutaneous; TCR, T-cell redirection therapy.
Clinical data cutoff date of September 2024.

Chari et al (2025)1,17 published the incidence of hematologic AEs from the post hoc analysis of phases 1 and 2 of the MonumenTAL-1 study at a median follow-up of 25.6 months (IQR, 8.5-25.9) for the 0.4 mg/kg SC QW cohort, 19.4 months (IQR, 9.2-20.7) for the 0.8 mg/kg SC Q2W cohort, and 16.8 months (IQR, 7.6-18.7) for the prior TCR-exposed cohort.

Safety Results


MonumenTAL-1 Study: Hematologic AEs1,17
Event, n (%)
0.4 mg/kg SC QWa,b
(N=143)
0.8 mg/kg SC Q2Wa,b
(N=154)
Prior TCRa,c
(N=78)
Grade 1/2
Grade 3
Grade 4
Grade 1/2
Grade 3
Grade 4
Grade 1/2
Grade 3
Grade 4
Grade 5
Neutropenia
6 (4)
29 (20)
15 (10)
11 (7)
24 (16)
9 (6)
3 (4)
18 (23)
19 (24)
0
Anemia
19 (13)
45 (31)
0
26 (17)
40 (26)
0
17 (22)
21 (27)
0
0
Thrombocytopenia
10 (7)
15 (10)
14 (10)
17 (11)
14 (9)
14 (9)
9 (12)
11 (14)
10 (13)
0
Leukopenia
12 (8)
6 (4)
5 (3)
11 (7)
14 (9)
4 (3)
3 (4)
8 (10)
6 (8)
0
Lymphopenia
3 (2)
17 (12)
20 (14)
6 (4)
14 (9)
26 (17)
2 (3)
4 (5)
9 (12)
0
Febrile neutropenia
-
-
-
-
-
-
0
4 (5)
0
0
Abbreviations: AE, adverse event; Q2W, every other week; QW, weekly; SC, subcutaneous; SUD, step-up dose; TCR, T-cell redirection therapy.
Clinical data cutoff date of October 11, 2023.
aReceived 2-3 SUDs.
bAEs are listed by frequency on an any-grade basis. AEs listed are grade 1-2 events occurring in at least 20% of patients in either group or grade 3 or worse occurring in at least 10% of patients in either group.
cAEs are listed by frequency on an any-grade basis and include those occurring in ≥10% of patients or grade ≥3 AEs occurring in ≥5%.

Schinke et al (2023)3 presented the incidence of hematologic AEs from the MonumenTAL-1 study at a median follow-up of 18.8 months for the 0.4 mg/kg SC QW cohort, 12.7 months for the 0.8 mg/kg SC Q2W cohort, and 14.8 months for the prior TCR-exposed cohort.

Safety Results


MonumenTAL-1 (Phase 2) Study: Hematologic AEs3
AE, n (%)
0.4 mg/kg SC QW
(n=143)
0.8 mg/kg SC Q2W
(n=145)
Prior TCR
(n=51)
Any Grade
Grade 3/4
Any Grade
Grade 3/4
Any Grade
Grade 3/4
Anemia
64 (44.8)
45 (31.5)
66 (45.5)
40 (27.6)
25 (49.0)
14 (27.5)
Neutropenia
50 (35.0)
44 (30.8)
41 (28.3)
32 (22.1)
28 (54.9)
27 (52.9)
Thrombocytopenia
39 (27.3)
29 (20.3)
43 (29.7)
27 (18.6)
19 (37.3)
15 (29.4)
Abbreviations: AE, adverse event; CTCAE, common terminology criteria for adverse events; QW, weekly; Q2W, every other week; SC, subcutaneous; TCR, T cell redirection therapy.
Clinical data cutoff date of 17 January 2023. These AEs were assessed per CTCAE v4.03.

CLINICAL DATA - MONUMENTAL-2 STUDY

MonumenTAL-2 (NCT05050097) is an ongoing, phase 1b, multi-arm, open-label study evaluating TALVEY in combination with other anticancer therapies in patients with MM.4-6

Study Design/Methods

  • Key eligibility criteria:
    • Cohort D: measurable MM, NDMM, ECOG PS of 0-1, and transplant ineligible or not intended for transplant.6
    • Cohort E: measurable MM; ≥2 prior LOTs, including a PI and an immunomodulatory drug; ECOG PS of 0-1; prior pomalidomide and prior TCR (CAR-T and BsAb) permitted; and no prior GPRC5D-targeted therapy.4

Cohort D

Nooka et al (2024)6 presented the incidence of hematologic AEs in the TALVEY 0.6 mg/kg Q2W + DARZALEX FASPRO + lenalidomide cohort at a median follow-up of 13.2 months (range, 10.0-14.6) and the TALVEY 0.8 mg/kg Q4W + DARZALEX FASPRO + lenalidomide cohort at a median follow-up of 5.8 months (range, 1.7 [denotes patients who died]-12.0).

Safety Results


MonumenTAL-2 Study (Cohort D): Summary of Hematologic TEAEs (≥30%)6
TEAE, n (%)
TALVEY 0.6 mg/kg Q2W + DARZALEX FASPRO + Lenalidomide
(n=8)
TALVEY 0.8 mg/kg Q4W + DARZALEX FASPRO + Lenalidomide
(n=26)
Any Grade
Grade 3/4
Any Grade
Grade 3/4
Neutropenia
6 (75.0)
6 (75.0)
12 (46.2)
11 (42.3)
Anemia
5 (62.5)
3 (37.5)
8 (30.8)
3 (11.5)
Thrombocytopenia
4 (50.0)
1 (12.5)
8 (30.8)
2 (7.7)
Abbreviations: Q2W, every other week; Q4W, every 4 weeks; TEAE, treatment-emergent adverse event.
Clinical data cutoff date of September 23, 2024.

Cohort E

Quach et al (2025)4 presented the incidence of hematologic AEs from the TALVEY + pomalidomide cohort of the MonumenTAL-2 study at a median follow-up of 20.7 months (range, 1.2-38.7).

Safety Results


MonumenTAL-2 (Cohort E): Hematologic TEAEs (≥25%)4
AE, %
Any Grade (%)
Grade 3/4 (%)
Neutropenia
68.6
65.7
Anemia
42.9
31.4
Thrombocytopenia
31.4
22.9
Abbreviations: AE, adverse event; TEAE, treatment-emergent adverse event.
Clinical data cutoff date of March 2025.

CLINICAL DATA - redirectt-1 STUDY - TALVEY + tecvayli COHORT

RedirecTT-1 (NCT04586426) is an ongoing, open-label, phase 1b/2 study evaluating the safety and efficacy of TALVEY and TECVAYLI in patients with RRMM, including those with EMD.7-10 

Study Design/Methods

  • Key eligibility criteria: relapsed or refractory or intolerant to established therapies including the last LOT, prior exposure to a PI, an immunomodulatory drug, and an anti-CD38 mAb.10

Usmani et al (2025)7 presented the incidence of hematologic AEs from the RedirecTT-1 phase 2 study in patients with RRMM and EMD at a median follow-up of 16.8 months.

Safety Results


RedirecTT-1 Study (EMD TALVEY + TECVAYLI Cohort): Hematologic AEs (≥30% Overall)7
AEa, %
TALVEY + TECVAYLI
(N=90)
Any grade
Maximum Grade 3/4
Neutropenia
72.2
63.3
Anemia
53.3
33.3
Thrombocytopenia
37.8
25.6
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events.
Clinical data cutoff date of July 18, 2025. Median follow-up 16.8 months.
aAEs graded by CTCAE v5.0. AEs were reported as treatment-emergent AEs recorded up to 30 days after the patient received last study treatment dose or until start of subsequent therapy.

Kumar et al (2025)8 presented the incidence of hematologic AEs from phase 2 of the RedirecTT-1 study at a median follow-up of 12.6 months (range, 0.5-19.5) in patients with RRMM and EMD.

Safety Results

  • At the data cutoff date of March 18, 2025, hematologic AEs were reported in patients with RRMM and EMD (N=90).
  • AEs were graded per CTCAE v5.0 and reported up to 30 days after the patient received the last dose of study treatment or until the start of subsequent antimyeloma therapy, whichever occurred first.
  • The most common grade 3/4 AEs were cytopenias and they were generally transient and resolved in 87% of patients.

Incidence of AEs

  • Any-grade neutropenia was reported in 72% of patients (n=65); grade 3/4 neutropenia in 62% of patients (n=56).
  • Any-grade anemia was reported in 51% of patients (n=46); grade 3/4 anemia in 31% of patients (n=28).
  • Any-grade thrombocytopenia was reported in 38% of patients (n=34); grade 3/4 thrombocytopenia in 26% of patients (n=23).

Mateos et al (2025)9 presented the incidence of hematologic AEs from phase 1b of the RedirecTT-1 study across all dose levels (dose levels 1-5) at a median follow up of 38 months, in patients with RRMM, including those with EMD.

Safety Results


RedirecTT-1 Study: Hematologic AEs (≥30% Overall)9 
AEa, %
All Dose Levels (N=94)
Any Grade
Grade 3/4
Neutropenia
74.5
70.2
Anemia
57.4
40.4
Thrombocytopenia
48.9
33.0
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; RP2R, recommended phase 2 regimen.
Clinical data cutoff date of July 2025. Median follow-up of 38.0 months for all doses levels and 34.5 months for the RP2R cohort.
aAEs graded by CTCAE v5.0.

Cohen et al (2025)10 published the incidence of hematologic AEs from the phase 1 dose-escalation segment of the RedirecTT-1 study across all-dose levels at a median follow-up of 20.3 months (range, 0.5-37.1) and in the RP2R cohort at 18.2 months.

Safety Results

  • At the data cutoff date of March 15, 2024, hematologic AEs were reported across all dose levels (N=94) and in the RP2R cohort (n=44).
  • AEs were graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and reported as TEAEs up to 30 days after the last dose of study treatment.

Incidence of AEs

  • Incidence of hematologic AEs in the RP2R cohort is presented in Table: RedirecTT-1 Study (TALVEY + TECVAYLI Cohort): Hematologic AEs in the RP2R Cohort.
  • Any-grade neutropenia was reported in 73% of patients (n=69), anemia in 56% of patients (n=53), and thrombocytopenia in 43% of patients (n=40) across all dose levels.
  • Grade 3/4 neutropenia was reported in 68% of patients (n=64), anemia in 38% of patients (n=36), and thrombocytopenia in 30% of patients (n=28) across all dose levels.
  • Febrile neutropenia was reported in 12.8% of patients.10,18

RedirecTT-1 Study (TALVEY + TECVAYLI Cohort): Hematologic AEs in the RP2R Cohort10,18
AEa, n (%)
RP2R
(n=44)
Any Grade
Grade 3/4
Neutropenia
30 (68.2)
25 (56.8)
Anemia
18 (40.9)
11 (25.0)
Thrombocytopenia
12 (27.3)
9 (20.5)
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; RP2R, recommended phase 2 regimen.
Clinical data cutoff date of March 15, 2024. Median follow-up time of 18.2 months.
aAEs were graded per CTCAE v5.0. AEs were reported up to 30 days after the patient received the last dose of study treatment. Patients could have had multiple AEs.

CLINICAL DATA - TRIMM-2 STUDY

TRIMM-2 (NCT04108195) ) is an ongoing, phase 1b, 2-part, multicohort, open-label study evaluating DARZALEX FASPRO regimens in combination with bispecific TCR antibodies with or without pomalidomide in patients with RRMM.11-13

Study Design/Methods

  • Key eligibility criteria12:
    • Double refractory to a PI and an immunomodulatory drug or received ≥3 prior LOTs (including a PI and an immunomodulatory drug).
    • Treatment with an anti-CD38 mAb (>90 days prior allowed), including anti-CD38 refractory patients.
    • Prior BsAb and CAR-T were allowed.

Chari et al (2025)12,19 published the incidence of hematologic AEs in the TALVEY 0.4 mg/kg QW + DARZALEX FASPRO and the TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO cohorts at a median follow-up of 18.6 months (range, 1.2-39.1).

Safety Results


TRIMM-2 Study (TALVEY + DARZALEX FASPRO Cohort): Hematologic AEs (≥25% Patients)a,19
AEb, n (%)
Any grade
(N=65)
Grade 3/4
(N=65)
Anemia
33 (51)
17 (26)
Neutropenia
26 (40)
19 (29)
Thrombocytopenia
25 (38)
15 (23)
Lymphopenia
19 (29)
17 (26)
Abbreviations: AE, adverse event; ASTCT, American Society for Transplantation and Cellular Therapy; CTCAE, Common Terminology Criteria for Adverse Events.
aData are presented for the combined TALVEY 0.4 mg/kg SC QW and 0.8 mg/kg SC Q2W cohorts.
bAEs were graded by CTCAE v5.0.
Clinical data cutoff date of November 17, 2023.

TRIMM-2 Study (TALVEY + DARZALEX FASPRO Cohort): Dose Modification Due to Hematologic AEs19
AE (≥3%), n (%)
All patients (N = 65)
Dose skips of TALVEY
   Anemia
2 (3)
   Thrombocytopenia
2 (3)
   Neutropenia
2 (3)
Dose skips of DARZALEX FASPRO
   Neutropenia
3 (5)
   Thrombocytopenia
3 (5)
Dose reductiona
   Anemia
1 (2)
   Neutropenia
1 (2)
Abbreviation: AE, adverse event.
aPatients could have experienced multiple AEs leading to dose reduction.
Clinical data cutoff date of November 17, 2023.

Bahlis et al (2024)11 presented the incidence of hematologic AEs in the TALVEY 0.4 mg/kg QW + DARZALEX FASPRO + pomalidomide cohort at a median follow-up of 15.8 months (range, 3.2-37.9) and the TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO + pomalidomide cohort at a median follow-up of 17.5 months (range, 0.2-37.7).

Safety Results


TRIMM-2 Study (TALVEY + DARZALEX FASPRO + Pomalidomide Cohort): Hematologic AEs11
AEa, n (%)
TALVEY 0.4 mg/kg QW + DARZALEX FASPRO + Pomalidomide
(n=18)
TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO + Pomalidomide
(n=59)
Any Grade
Grade 3/4
Any Grade
Grade 3/4
Neutropenia
15 (83.3)
14 (77.8)
47 (79.7)
42 (71.2)
Anemia
9 (50.0)
6 (33.3)
30 (50.8)
22 (37.3)
Thrombocytopenia
6 (33.3)
4 (22.2)
31 (52.5)
20 (33.9)
Leukopenia
4 (22.2)
4 (22.2)
22 (37.3)
19 (32.2)
Lymphopenia
9 (50.0)
9 (50.0)
16 (27.1)
16 (27.1)
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; Q2W, every other week; QW, weekly.
Clinical data cutoff date of July 29, 2024.
aAEs were graded by CTCAE v5.0.

CLINICAL DATA - TRIMM-3 Study - TALVEY + CETRELIMAB COHORT

TRIMM-3 (NCT05338775) is a phase 1b, nonrandomized, open-label study evaluating the dosing, safety, and tolerability of TALVEY in combination with cetrelimab in patients with RRMM.14,15

Study Design/Methods

  • Key eligibility criteria14:
    • MM per IMWG criteria
    • RRMM who may not be eligible for or expected to benefit from available therapies
    • ECOG PS 0 or 1

Perrot et al (2025)14 presented the incidence of hematologic AEs of the TALVEY + cetrelimab cohort at a median follow-up of 11.5 months (range, 1.5-32.3).

Safety Results


TRIMM-3 Study: Hematologic AEs (≥10% Overall)14 
AEa, n (%)
All Patients
(N=44)
Any Grade
Grade 3/4
Anemia
26 (59.1)
17 (38.6)
Neutropenia
24 (54.5)
19 (43.2)
Thrombocytopenia
16 (36.4)
7 (15.9)
Lymphopenia
12 (27.3)
12 (27.3)
Leukopenia
6 (13.6)
4 (9.1)
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events.
Clinical data cutoff date of April 2, 2025.
aAEs were graded per CTCAE v5.0. AEs reported were treatment emergent.

literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 09 February 2026.

 

References

Show
1 Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025;12(4):e269-e281.  
2 Rasche L, Schinke C, Touzeau C, et al. Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: analyses at an extended median follow-up. Poster presented at: The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting; May 30-June 3, 2025; Chicago, IL/Virtual.  
3 Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5DxCD3 bispecific antibody, for relapsed/refractory multiple myeloma. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6, 2023; Chicago, IL/Virtual.  
4 Quach H, Perrot A, Matous JV, et al. Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with relapsed/refractory multiple myeloma: updated safety and efficacy results from the phase 1b MonumenTAL-2 study. Poster presented at: The 67th American Society of Hematology (ASH) Annual Meeting; December 6-9, 2025; Orlando, FL.  
5 Janssen Research & Development, LLC. A multi-arm phase 1b study of talquetamab with other anticancer therapies in participants with multiple myeloma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT05050097 NLM Identifier NCT05050097.  
6 Nooka AK, Cochrane T, D’Souza A, et al. Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma: safety and efficacy results from the phase 1b MonumenTAL-2 study. Poster presented at: The 66th American Society of Hematology (ASH) Annual Meeting; December 7-10, 2024; San Diego, CA.  
7 Usmani SZ, Kumar S, Mateos MV, et al. Efficacy and safety of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease: updated phase 2 results from the RedirecTT-1 study with extended follow-up. Oral Presentation presented at: the 67th American Society of Hematology (ASH) Annual Meeting; December 6-9, 2025; Orlando, FL.  
8 Kumar S, Mateos MV, Ye JC, et al. Dual targeting of extramedullary myeloma with Talquetamab and Teclistamab. N Engl J Med. 2026;394(1):51-61.  
9 Mateos MV, Magen H, Gatt M, et al. Safety and efficacy of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma from phase 1b of RedirecTT-1: results with an extended median follow-up of 3 years. Oral presentation presented at: the 67th American Society of Hematology (ASH) Annual Meeting; December 6-9, 2025; Orlando, FL.  
10 Cohen YC, Magen H, Gatt M, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392(2):138-149.  
11 Bahlis N, van de Donk NWCJ, Reece D, et al. Talquetamab + daratumumab + pomalidomide in patients with relapsed/refractory multiple myeloma: results from the phase 1b TRIMM2 study. Oral Presentation presented at: 21st International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio de Janeiro, Brazil.  
12 Chari A, van de Donk NWCJ, Dholaria B, et al. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025;146(24):2902-2913.  
13 Janssen Research & Development, LLC. A phase 1b study of subcutaneous daratumumab regimens in combination with bispecific T cell redirection antibodies for the treatment of subjects with multiple myeloma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04108195 NLM Identifier: NCT04108195.  
14 Perrot A, Touzeau C, Rodríguez-Otero P, et al. Talquetamab + cetrelimab in patients with relapsed/refractory multiple myeloma: initial safety and efficacy results from the phase 1b TRIMM-3 study. Oral Presentation presented at: the European Hematology Association (EHA) Annual Meeting; June 12-15, 2025; Milan, Italy.  
15 Janssen Research & Development, LLC. A phase 1b study of bispecific T cell redirection antibodies in combination with checkpoint inhibition for the treatment of participants with relapsed or refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 9]. Available from: https://clinicaltrials.gov/study/NCT05338775 NLM Identifier: NCT05338775.  
16 Jakubowiak AJ, Anguille S, Karlin L, et al. Updated results of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1/2 MonumenTAL-1 study. Poster presented at: The 65th American Society of Hematology (ASH) Annual Meeting; December 9-12, 2023; San Diego, CA/Virtual.  
17 Chari A, Touzeau C, Schinke C, et al. Supplement to: Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025;12(4):e269-e281.  
18 Cohen YC, Magen H, Gatt M, et al. Talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma: updated phase 1b results from RedirecTT-1 with >1 year of follow-up. Oral Presentation presented at: 21st International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio de Janeiro, Brazil.  
19 Chari A, van de Donk NWCJ, Dholaria B, et al. Supplement to: Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025;146(24):2902-2913.